Veterinary Medicines Directorate

United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS
(Reference Member State)

MUTUAL RECOGNITION PROCEDURE
PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Maximec Horse Oral Paste 18.7 mg/g

PuAR correct as of 15/03/2018 when RMS was transferred to NL. Please contact the RMS for future updates

MODULE 1

PRODUCT SUMMARY

EU Procedure number	UK/V/0230/001/MR
Name, strength and pharmaceutical form	Maximec Horse Oral Paste 18.7 mg/g
Applicant	Cross Vetpharm Group Ltd Broomhill Road Tallaght Dublin 24 Ireland
Active substance	Ivermectin
ATC Vetcode	QP54AA01
Target species	Horses
Indication for use	Treatment of parasitic infestations in horses due to large strongyles, small strongyles, lungworms, pinworms, ascarids, hairworms, large-mouth stomach worms, neck threadworms, intestinal threadworms and stomach bots.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies (veterinary) (HMA(v)) website (www.HEVRA.org).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Mutual recognition application in accordance with Article 13.1.a (iii) of Directive 2001/82/EC as amended.
Date of completion of the original mutual recognition procedure	23rd February 2007
Date product first authorised in the Reference Member State (MRP only)	23rd September 2005
Concerned Member States for original procedure	Belgium Luxembourg The Netherlands

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC[1].
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

[1] SPC = Summary of product characteristics

II. QUALITY ASPECTS

A. Composition

The product contains ivermectin 18.7 mg/g and the excipients maize oil, polysorbate 80, apple flavour and silica colloidal anhydrous.

The container/closure system is a multi-dose oral syringe comprising a high density polyethylene (HDPE) syringe barrel and a low density polyethylene (LDPE) cap. The plunger and multi-dose sliding ring are formed from HDPE and the plunger seal is formed from LDPE. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation is justified.
The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is ivermectin an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The applicant refers to a certificate of suitability (CEP) for ivermectin

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

Certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

E. Control on intermediate products

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been

justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

H. Genetically Modified Organisms

Not applicable.

J. Other Information

Shelf life: 2 years.
Storage condition: Protect from light

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

Since the application is made in accordance with Article 13.1 (a) (iii) of Directive 2001/82/EC as amended on the basis of essential similarity, data on pharmacodynamics and pharmacokinetics are not required. This type of product is exempt from the requirements to provide bioequivalence studies.

Toxicological Studies

Since the application is made in accordance with Article 13.1 (a) (iii) of Directive 2001/82/EC as amended on the basis of essential similarity this information is not required.

User Safety

The risk management measures that the applicant proposes for this product are the same as for the reference product (Eqvalan Paste). The same warnings are in the relevant section of the SPC for this product as for the reference product

and are adequate to ensure safety to users of the product. The SPC presented confirms this.

Do not smoke, drink or eat while handling the product. Wash hands after use.

Ecotoxicity

Since the application is made in accordance with Article 13.1 (a) (iii) of Directive 2001/82/EC as amended, on the basis of essential similarity, data on ecotoxicity are not required. This product is considered to be bioequivalent to the reference product (Eqvalan Paste) and environmental safety is considered to be satisfactory.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

III.B Residues documentation

Residue Studies

Since the application is made in accordance with Article 13.1 (a) (iii) of Directive 2001/82/EC as amended on the basis of essential similarity this information is not required.

MRLs

Ivermectin is listed in Annex I of Council Regulation 2377/90. The marker substance is 22,23-dihydroavermectin $B1_a$

MRLs are listed below:

	Cattle	Pig	Sheep
Liver	100 µg/kg	15 µg/kg	15 µg/kg
Fat	40 µg/kg	20 µg/kg	20 µg/kg

Withdrawal Periods

Based on the data provided above, a withdrawal period of 21 days for meat and offal in horses is justified. Animals must not be slaughtered for human consumption during treatment. The product is not permitted for use in lactating mares producing milk for human consumption.

It is considered that essential similarity has been demonstrated and therefore the proposed withdrawal period is considered satisfactory.

IV CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

Pharmacology

Since the application is made in accordance with Article 13.1 (a) (iii) of Directive 2001/82/EC as amended on the basis of essential similarity this information is not required as it has already been presented for the reference product (Eqvalan Paste).

Tolerance in the Target Species of Animals

Since the application is made in accordance with Article 13.1 (a) (iii) of Directive 2001/82/EC as amended on the basis of essential similarity this information is not required as it has already been presented for the reference product.

IV.B Clinical Studies

Laboratory Trials

Since the application is made in accordance with Article 13.1 (a) (iii) of Directive 2001/82/EC as amended on the basis of essential similarity, this information is not required as it has already been presented for the reference product.

Field Trials

Since the application is made in accordance with Article 13.1 (a) (iii) of Directive 2001/82/EC as amended on the basis of essential similarity, this information is not required as it has already been presented for the reference product.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)